Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ferucarbotran→

Ferucarbotran Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Superparamagnetic iron-oxide nanoparticle MRI contrast agentliver-specific reticuloendothelial contrast medium
Mechanism of action
Carboxydextran-coated superparamagnetic iron oxide nanoparticles are phagocytosed by Kupffer cells in the hepatic reticuloendothelial system. Their strong T2 and T2* relaxivity reduces signal intensity in normal liver parenchyma, increasing contrast between normal liver and lesions with reduced Kupffer-cell uptake.
Indications / reported uses
  • Contrast enhancement for magnetic resonance imaging of focal liver lesions, particularly to improve lesion detection and characterisation in the liver, under product authorisation.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC2727962/ · https://pubmed.ncbi.nlm.nih.gov/23256052/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC4611768/ · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Superparamagnetic iron-oxide nanoparticle MRI contrast agent; liver-specific reticuloendothelial contrast medium

Mechanism of action

Carboxydextran-coated superparamagnetic iron oxide nanoparticles are phagocytosed by Kupffer cells in the hepatic reticuloendothelial system. Their strong T2 and T2* relaxivity reduces signal intensity in normal liver parenchyma, increasing contrast between normal liver and lesions with reduced Kupffer-cell uptake.

General use cases

  • Contrast enhancement for magnetic resonance imaging of focal liver lesions, particularly to improve lesion detection and characterisation in the liver, under product authorisation.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Ferucarbotran Environmental Risk Assessment (ERA) (the Ferucarbotran ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.